LYFE Capital
VC Fund
Shanghai, China
LYFE Capital is a pure play healthcare focused investment firm. We believe that “Healthcare has no boundaries”, and that every new choice we made has the potential to advance healthcare and solve the unmet needs for everyone. LYFE Capital operates 5 global offices including our US headquarters in Menlo Park, California, our Asia headquarters inSingapore, as well as locations in Seoul, Tokyo and Shanghai. We leverage our expertise and global resources to invest in and create value for healthcare companies across the globe. LYFE Capital’s investments span medical devices, therapeutics, diagnostics, and emerging sectors across North America and Asia.
- Total investments:
- 82
- Last investment:
- Lead investor:
- 43%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries LYFE Capital invests in
Stages LYFE Capital invests in
Countries LYFE Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $11M–$85M
- Series B
- $15M–$148M
- Series C
- $14M–$142M
Investment Focus
Industry
- Biotechnology 37 (45%)
- Health Care 36 (44%)
- Medical 17 (21%)
- Pharmaceutical 10 (12%)
- Therapeutics 8 (10%)
Stage
- Series B 23 (28%)
- Series A 21 (26%)
- Series C 13 (16%)
- Series D 4 (5%)
- Seed 3 (4%)
Country
- China 40 (49%)
- United States 13 (16%)
- France 1 (1%)
- Israel 1 (1%)
- South Korea 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
James Zhao
Founder and Partner
|
Founder and Partner | Total investments: 3 | Find email | |
Drake Yu
Founder
|
Founder | Total investments: 1 | Find email | |
Roy Xu
CFO
|
CFO | Total investments: 0 | Find email | |
|
Wang Yinan
Partner
|
Partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Starna Therapeutics offers development of innovative drugs with RNA as the core, and has an industry-leading RNA and organ-selective delivery technology platform with independent intellectual property rights; the company has established a rich R&D pipeline , covering infectious disease vaccines, tumor immunity and other fields. | $40M / Series B / May 12, 2026 | ||
| Aspen Neuroscience is a development stage and private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinson's disease. It is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmetmedical needs, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson's disease (PD) and extending across the brain and affected organs. | $115M / Series C / Nov 20, 2025 | ||
| Starna Therapeutics offers development of innovative drugs with RNA as the core, and has an industry-leading RNA and organ-selective delivery technology platform with independent intellectual property rights; the company has established a rich R&D pipeline , covering infectious disease vaccines, tumor immunity and other fields. | $42.1M / Series B / Oct 24, 2025 | ||
ALLYRNA Pharmaceuticals
|
ALLYRNA, an innovative small molecule drug developer focused on first-in-class drug development, has established a unique platform for radiotherapy and immunotherapy sensitizers. | $10M / Seed / Aug 27, 2025 | |
| Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs. | $102M / Series F / Apr 03, 2025 | ||
| Verdiva Bio is a company creating cutting-edge treatments that improve results for patients with obesity, cardiometabolic diseases, and associated problems by making treatment options more patient-friendly. | $411M / Series A / Jan 09, 2025 | ||
| CytoTronics is designing and developing cell culture plates with embedded high-density electronic systems. | $13.5M / Seed / Sep 05, 2024 | ||
| Koru Pharma is a biopharma company that develops and manufacture medical products for skin. | Secondary Market / Apr 01, 2024 | ||
| Precision BioSciences is a biotechnology company dedicated to improving lives through its next-generation gene editing technology, ARCUS.Precision BioSciences’ mission is to translate the world’s most powerful genome editing technology into greatly needed products throughout the life sciences. Precision’s proprietary ARCUS genome editingtechnology enables the production of highly specific nucleases that can insert, remove, and modify DNA at essentially any location in a complex genome. | $40M / Post-IPO Equity / Mar 01, 2024 | ||
| ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer. | $112M / Series B / Feb 13, 2024 | ||
| See all 82 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does LYFE Capital invest in?
LYFE Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 82 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is LYFE Capital's check size?
LYFE Capital typically joins rounds of $11M–$85M at Series A, $15M–$148M at Series B and $14M–$142M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds LYFE Capital participates in.
How do I contact LYFE Capital?
Public channels for LYFE Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at LYFE Capital?
The team at LYFE Capital includes James Zhao (Founder and Partner), Drake Yu (Founder) and Roy Xu (CFO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
